Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Ovarian Neoplasms 6Carcinoma, Non-Small-Cell Lung 4Fallopian Tube Neoplasms 3Carcinoma, Ovarian Epithelial 3Breast Neoplasms 3Non Small Cell Lung Carcinoma NSCLC 2NSCLC 2Melanoma 2Triple Negative Breast Neoplasms 1Recurrence 1Primary Breast Cancer 1Non-Small Cell Lung Cancer With HER2- Mutations 1Neoplasm Metastasis 1Lung Neoplasms 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1Carcinoma 1

Interventions

osimertinib 3Vinorelbine 3Pemetrexed 3Cisplatin 3Carboplatin 3Gemcitabine 2Gefitinib 2Docetaxel 2CP protocol 2rezivertinib 1pembrolizumab 1aumolertinib 1Taxes 1Paclitaxel 1HMPL-013 1HM781-36B 1Erlotinib Hydrochloride 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × NSCLC × CP protocol × Clear all
NCT00576225 2020-10-19

CT-2103/Carboplatin vs Paclitaxel/Carboplatin for NSCLC in Women With Estradiol > 25 pg/mL

CTI BioPharma

Phase 3 Withdrawn
Thoracic

NSCLC

NCT00298415 2013-10-25

Chemotherapy of Elderly Patients With Non-Small-Cell Lung Cancer (NSCLC)

Intergroupe Francophone de Cancerologie Thoracique

Phase 3 Completed
451 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡